HMPL 689

Drug Profile

HMPL 689

Alternative Names: HMPL-689

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Non-Hodgkin's lymphoma

Most Recent Events

  • 29 Aug 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy) in China (PO) (NCT03128164; 9221910)
  • 28 Feb 2017 Hutchison Medipharma completes a phase I trial in Haematological malignancies (In volunteers) in Australia (PO) (NCT02631642)
  • 02 Aug 2016 Hutchison MediPharma plans a phase I trial for Haematological malignancies in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top